LabCorp

MetasTx appoints Jennifer Quigley to its Advisory Board; her experience in diagnostics and precision medicine will aid in advancing the company's mission to improve cancer treatment through innovative therapies.

The Global Precision Medicine Market report covers industrial and commercial aspects, market driving forces, key players' strategies, and regional landscape. It includes detailed vendor profiles, market trends, share analysis, and forecasts from 2024 to 2032.

The Virtual Clinical Trials Market is projected to grow from USD 2.64 billion in 2023 to USD 7.11 billion by 2029, at a CAGR of 17.95%. Key drivers include breaking barriers in women's health studies, integration of advanced systems, and a more patient-centric approach. Challenges include ethical considerations and regulatory compliance. The market is segmented by study type, phases, company size, and therapeutic area, with North America leading in adoption.

The Virtual Clinical Trials Market is expected to grow from USD 2.64 billion in 2023 to USD 7.11 billion by 2029, at a CAGR of 17.95%. Key trends include breaking barriers in women's health studies, integration of advanced systems, and a more patient-centric approach. Challenges include ethical considerations and regulatory compliance. North America leads in market dominance.

The United States Remote Clinical Trials Market is projected to reach USD xx.x billion by 2031, growing at a CAGR of xx.x% from 2024. Key market players include Medidata, IQVIA, Labcorp, and others. The market is segmented by type (interventional, observational, expanded access) and application (oncology, cardiovascular, others). Regional analysis highlights North America's mature offshore oil and gas fields, Europe's offshore wind energy projects, and Asia-Pacific's growing energy demand driving market growth. Challenges include regulatory scrutiny, environmental activism, and geopolitical tensions.

AG Mednet expands leadership with Catherine Tyner as Head of Clinical Strategy and Jamie Russo as Head of Product to meet growing demand for Judi platform, which is used in over 2,000 clinical trials globally.

The Global Oncology Based In Vivo (CRO) Market is projected to grow from USD 2.07 Billion in 2024 to USD 3.61 Billion by 2031, driven by increasing cancer prevalence, biotechnology advances, and R&D investments. Key challenges include high costs, model limitations, ethical considerations, and data standardization issues. North America leads the market, while Asia Pacific shows the fastest growth. Major players include Charles River Laboratory, ICON Plc, and Thermo Fisher Scientific.

Multiple biotech companies raise significant funds for various medical advancements, including $600M for Symbiotic Capital targeting biotechnology, medical devices, diagnostics, and synthetic biology; $165M Series A for Third Arc Bio's multifunctional antibodies for oncology and autoimmunity; $144M Series B for Outpace Bio's AI-powered cell therapies for solid tumors; and others ranging from $126M for Halda Therapeutics' RIPTAC cancer therapies to $5M for Kano Therapeutics' targeted, non-viral DNA insertion technology.